Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky

ملخص مفصل
TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential…
TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on behalf of shareholders who lost money.
NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Sellers drove Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares sharply lower on November 9, 2026, after the Company reported third-quarter TRYNGOLZA sales of $9.3 million and cut the drug's full-year sales guidance to roughly $50 million from $100-$110 million. If you bought IONS and are now holding losses, you may have legal rights, and Levi & Korsinsky is investigating. IONS shareholders who lost money are encouraged to submit their loss details for a free review . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Ionis beat consensus estimates on both revenue and earnings per share. Shares fell anyway. Third-quarter commercial revenue rose 18% year over year, which the Company attributed primarily to DAWNZERA product sales. TRYNGOLZA sales, however, were only $9.3 million, compared with $31.8 million in the third quarter of 2025.
TRYNGOLZA recorded approximately $32 million in first-half 2026 sales. To reach the prior $100-$110 million target, the drug needed roughly $68-$78 million over the final six months. The third quarter delivered $9.3 million. The revised full-year figure of roughly $50 million sits $50-$60 million below the original range.
If you are holding IONS losses after the November 9 sell-off, see if you may be eligible to recover your IONS losses or call (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Q: How much did IONS stock drop? A: IONS shares fell roughly $7.27, or about 18.44% to open at approximately $32.15 on November 9, 2026, after the Company disclosed that it had cut its…
Q: Which…
مطلع المقال، مقتطف من PR Newswire. لقراءة المقال كاملًا، افتحه على موقع الناشر.
يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)
